Get the Stockscreener App
10.06
4.03%
0.39
After Hours:
10.33
0.27
+2.68%
Arcus Biosciences Inc stock is traded at $10.06, with a volume of 972.09K.
It is up +4.03% in the last 24 hours and up +7.82% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$9.67
Open:
$9.79
24h Volume:
972.09K
Relative Volume:
0.97
Market Cap:
$1.07B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-3.2557
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
+6.01%
1M Performance:
+7.82%
6M Performance:
-20.79%
1Y Performance:
-35.68%
1-Day Range:
$9.74
$10.23
1-Week Range:
$8.88
$10.74
52-Week Range:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
10.06 | 1.03B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Will Arcus Biosciences Inc. Hold Gains Into CloseReliable Alerts for Daily Stock Movers Released - beatles.ru
Arcus Biosciences Q2 Earnings and Catalysts Ahead: A Risky Buy for 12 Months - AInvest
Arcus BiosciencesA Risky Buy Ahead Of Pivotal, Catalyst Rich 12 Months (NYSE:RCUS) - Seeking Alpha
Trapped Investors in Arcus Biosciences Inc. Await Breakout SignalNews Based Entry Opportunity Alerts Detected - beatles.ru
Arcus Biosciences, Inc. (NYSE:RCUS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Arcus Biosciences Inc. Stock Recovery Path — Analyst BreakdownReal Time Stock Movement Analysis Indicates Breakout - beatles.ru
Gilead and Arcus Advance Promising Colorectal Cancer Study - TipRanks
Arcus Biosciences Tops Revenue Forecasts And Drives Pipeline Growth - Finimize
Gilead and Arcus Biosciences’ Promising Study on Advanced Gastrointestinal Cancers - TipRanks
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $14 to $52 - 富途牛牛
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2 - MSN
Wells Fargo Adjusts Price Target for Arcus Biosciences (RCUS) | - GuruFocus
H.C. Wainwright Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Morgan Stanley Lifts Price Target on Arcus Biosciences to $23 From $22, Keeps Overweight Rating - MarketScreener
Decoding Arcus Biosciences Inc (RCUS): A Strategic SWOT Insight - GuruFocus
Arcus Biosciences Reports Strong Q2 2025 Results - TipRanks
Arcus Biosciences earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Arcus Biosciences Q2 revenue beats analyst expectations - MarketScreener
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update - Stock Titan
Is Arcus Biosciences (NYSE:RCUS) Using Debt In A Risky Way? - 富途牛牛
When is Arcus Biosciences Inc. stock expected to show significant growthIdentify undervalued stocks ready to soar - Jammu Links News
How volatile is Arcus Biosciences Inc. stock compared to the marketTremendous gains - Jammu Links News
What are the technical indicators suggesting about Arcus Biosciences Inc.Free Wealth Planning Blueprint - Jammu Links News
What institutional investors are buying Arcus Biosciences Inc. stockHigh-yield investments - Jammu Links News
Should I hold or sell Arcus Biosciences Inc. stock in 2025Unlock powerful portfolio management tools - Jammu Links News
How does Arcus Biosciences Inc. compare to its industry peersOutstanding capital appreciation - Jammu Links News
What are the latest earnings results for Arcus Biosciences Inc.Outstanding risk-reward balance - Jammu Links News
Why is Arcus Biosciences Inc. stock attracting strong analyst attentionRealize consistent double-digit growth - Jammu Links News
Does Arcus Biosciences Inc. stock perform well during market downturnsTremendous gains - Jammu Links News
What catalysts could drive Arcus Biosciences Inc. stock higher in 2025Free Stock Movement Tracking - Jammu Links News
Arcus Biosciences’ Pancreatic Cancer Drug Quemliclustat Receives Orphan Drug Designation from FDA - MSN
How does Arcus Biosciences Inc. generate profit in a changing economyPost Market Planner That Work - Jammu Links News
Arcus Biosciences Advances Phase 1 Study of AB521 in Cancer Treatment - TipRanks
Will Arcus Biosciences Inc. bounce back from current supportEarly Breakout Entry Point Notifications Sent - metal.it
Why Arcus Biosciences Inc. stock attracts strong analyst attentionConsistent Income Focused Trade List Analyzed - beatles.ru
How many analysts rate Arcus Biosciences Inc. as a “Buy”Advanced Screener Report With Low Risk - Jammu Links News
Arcus Biosciences’ Phase 3 Trial: A Potential Game-Changer in Pancreatic Cancer Treatment - TipRanks
Arcus Biosciences Inc.’s Price Action Aligns with Quant SignalsHigh Yield Stock Screening Results Explained - metal.it
Arcus Biosciences’ SWOT analysis: HIF-2alpha program drives stock outlook By Investing.com - Investing.com South Africa
Arcus Biosciences Inc. Shows Risk Reward Favoring UpsideReal Trader Watchlist of Hot Stocks Released - metal.it
Is it the right time to buy Arcus Biosciences Inc. stockSuperior returns - Jammu Links News
What is Arcus Biosciences Inc. company’s growth strategyMaximize your portfolio’s growth potential - Jammu Links News
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):